Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22702800 | 1.00 | MGLL (0.48) | MGLLABHD6SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL20270278 | 1.00 | MGLL (0.48) | MGLLABHD6SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL21029363 | 1.00 | MGLL (0.48) | MGLLABHD6SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL26933511 | 0.85 | SLC6A4 (0.44) | MGLLABHD6SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL26933516 | 0.85 | SLC6A4 (0.44) | MGLLABHD6SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6411918 | 0.84 | EPHX2 (0.48) | MGLLABHD6SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL30636396 | 0.84 | MGLL (0.44) | MGLLABHD6SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL22702905 | 0.81 | MGLL (0.46) | MGLLABHD6SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6284659 | 0.80 | PDK2 (0.47) | MGLLABHD6SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3127016 | 0.80 | SLC6A4 (0.54) | MGLLABHD6SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3555055-B1 | HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2022-08-03 | — | — | EP | disclosed |
| US-10934278-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| US-10864211-B2 | Hydroxy isoxazole compounds useful as GPR120 agonists | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3490977-B1 | CYCLOBUTANE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED POTASSIUM CHANNELS | AUTIFONY THERAPEUTICS LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| US-20190269679-A1 | HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190161479-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2019-05-30 | — | — | US | disclosed |
| WO-2018020263-A1 | CYCLOBUTANE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED POTASSIUM CHANNELS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934278-B2 | Compounds | KCNA3, KCNN3, KCND3 | MGLL 3630/4885ABHD6 3303/4885SLC6A4 312/4885 |
| US-10864211-B2 | Hydroxy isoxazole compounds useful as GPR120 agonists | GPR119, GPR88, GPR180 | MGLL 268/4885ABHD6 1080/4885SLC6A4 2073/4885 |
| US-20190269679-A1 | HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR88, GPR180 | MGLL 268/4885ABHD6 1080/4885SLC6A4 2073/4885 |
| US-20190161479-A1 | NOVEL COMPOUNDS | KCNN3, KCNA3, KCND3 | MGLL 3549/4885ABHD6 3103/4885SLC6A4 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.